Hepatocellular Carcinoma
Conditions
Brief summary
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of cancer-related death worldwide. Recurrence of tumor within the liver remnant is common, with a reported 5-year recurrence rate of 70%. Repeat hepatectomy is an effective treatment for intrahepatic HCC but with a small proportion of resection rate because of the poor functional liver reserve and postoperative complications. Radiofrequency ablation(RFA) is becoming the main effective treatment for small HCC (≤5.0cm). The efficacy of RFA for recurrent HCC has been reported to be comparable to those achieved by surgery with minimal, but higher local recurrence rate after RFA. It has been reported that immunotherapy in patients who underwent curative treatment for HCC, adjuvant immunotherapy with activated CIK cells increased recurrence-free and overall survival. But there is little evidence for adjuvant immunotherapy of recurrence HCC. Cytotoxic T lymphocytes(CTL), a kind of effective T cells that specific recognizing and killing antigen targeted cells through cloning amplification after receiving antigen information from antigen presented cell and playing key role to clear cancerous cells. So our hypothesis is that RFA combined with immunotherapy (Highly-purified CTL) is superior to RFA for recurrent HCC. The aim of this prospective study is to compare the outcome of RFA combined with immunotherapy (Highly-purified CTL) with RFA for small recurrent HCC after partial hepatectomy.
Interventions
PROCEDURERFA
Radiofrequency ablation(RFA)for small recurrent HCC
PROCEDURERFA+highly-purified CTL
Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
Sponsors
Ming Kuang
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. age 18-75 years; 2. recurrence of HCC 12 months after initial hepatectomy; 3. no other treatment received except for the initial hepatectomy; 4. single tumor≤5.0cm in diameter; or 2-3 lesions each≤3.0cm; 5. lesions visible on ultrasound and with an acceptable and safe path between the lesion and the skin as shown on ultrasound; 6. no severe coagulation disorders (prothrombin activity\<40% or a platelet count\<40,000/mm3); 7. Eastern Co-operative Oncology Group performance(ECOG) status 0-1.
Exclusion criteria
1. Pregnant women, breastfeeding women or plan pregnancy for the future 2 years; 2. The presence of vascular invasion or extrahepatic spread onimaging; 3. Usage of strong immunosuppressive agents such as corticosteroids, cyclosporine A within six months or longer; 4. HIV antibody or HCV antibody positive; 5. Immunodeficiency diseases or autoimmune diseases (such as rheumatoid arthritis, Buerger's disease, multiple sclerosis and type 1 diabetes); 6. Suffering with cancers (except skin cancer, prostate cancer or cervical carcinoma in situ) at the enrolling time or 5 years before; 7. Suffering with other organ failure; 8. Suffering with severe mental illness; 9. Drug addiction (including alcohol) for 1 year before the enrolling time; 10. Participate in other Clinical trials within three months prior to 3 months before the enrolling time; 11. Other researchers believe that the patient is not fit for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 5 years |
| Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 | 1 month |
Countries
China
Outcome results
None listed